<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="4" ids="30413">Heme</z:chebi> oxygenase-1 (HO-1, HSP32) is an early gene that is responsive to an array of pathological conditions including, but not limited to, <z:mp ids='MP_0005039'>hypoxia</z:mp> and <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>HO-1 cleaves the <z:chebi fb="4" ids="30413">heme</z:chebi> molecule and produces <z:chebi fb="168" ids="17245">carbon monoxide</z:chebi> (CO) and <z:chebi fb="0" ids="17033">biliverdin</z:chebi> (an <z:chebi fb="11" ids="22586">antioxidant</z:chebi>) and is essential for iron homeostasis </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this study was to investigate, using transgenic (Tg) mice, whether overexpression of HO-1 in the brain augments or attenuates cellular injury caused by <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Homozygous HO-1 Tg mice that overexpress HO-1 under the control of the neuron-specific enolase promoter (characterized previously) were used </plain></SENT>
<SENT sid="4" pm="."><plain>Under <z:chebi fb="2" ids="5615">halothane</z:chebi> anesthesia and normothermic conditions, <z:mp ids='MP_0002169'>wild-type</z:mp> nontransgenic (nTg; n = 22) and HO-1 Tg (n = 24) mice were subjected to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo) </plain></SENT>
<SENT sid="5" pm="."><plain>Six hours after induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, Tg and nTg mice developed <z:mpath ids='MPATH_124'>infarcts</z:mpath> that were 39 +/- 6 and 63 +/- 9 mm3, respectively (p &lt; 0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>No significant difference between the two strains was observed in the values of <z:hpo ids='HP_0002181'>brain edema</z:hpo> (11.3 +/- 4% in Tg vs. 14.6 +/- 5% in nTg; p &lt; 0.1) </plain></SENT>
<SENT sid="7" pm="."><plain>At 24 h after MCAo, Tg mice exhibited significant neuroprotection as determined by the <z:hpo ids='HP_0001297'>stroke</z:hpo> volumes (41 +/- 2 mm3 in Tg vs. 74 +/- 5 mm3 in nTg; p &lt; 0.01) and values of ischemic <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> (21 +/- 6% in Tg vs. 35 +/- 11% in nTg; p &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Data suggest that neuroprotection in Tg mice was, at least in part, related to the following findings: (a) constitutively up-regulated cyclic <z:chebi fb="10" ids="17345">GMP</z:chebi> and bcl-2 levels in neurons; (b) inhibition of nuclear localization of p53 protein; and (c) <z:chebi fb="11" ids="22586">antioxidant</z:chebi> action of HO-1, as detected by postischemic neuronal expression of ferritin, and decreases in iron staining and tissue <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation </plain></SENT>
<SENT sid="9" pm="."><plain>We suggest that pharmacological stimulation of HO-1 activity may constitute a novel therapeutic approach in the amelioration of ischemic injury during the <z:hpo ids='HP_0011009'>acute</z:hpo> period of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>